search
Back to results

Use of In-Line Filtration in Critically Ill Children

Primary Purpose

Critical Illness

Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Filter: NOE96E, ELD96E, NLF1E, TNA1E
Sponsored by
Hannover Medical School
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Critical Illness focused on measuring pediatric intensive care, critically ill children, in-line filtration, prospective randomized study, complications, sepsis, SIRS, thrombosis, organ failure

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Children admitted to pediatric intensive care unit (PICU) Exclusion Criteria: Suspected death within 48 hours Duration of PICU stay less than 6 hours Patients recruited for Simulect or Sintra Study

Sites / Locations

  • Hannover Medical School

Outcomes

Primary Outcome Measures

Sepsis
Thrombosis
SIRS
Organ failure
Composite primary outcome including "sepsis, SIRS, thrombosis, organ failure"

Secondary Outcome Measures

Duration of Pediatric Intensive Care Unit stay
Duration of overall hospital stay

Full Information

First Posted
September 13, 2005
Last Updated
November 28, 2008
Sponsor
Hannover Medical School
Collaborators
Pall Corporation, B. Braun Melsungen AG
search

1. Study Identification

Unique Protocol Identification Number
NCT00209768
Brief Title
Use of In-Line Filtration in Critically Ill Children
Official Title
Randomised, Prospective Study of the Use of In-Line Filtration on the Reduction of Complication Rate in Critically Ill Children
Study Type
Interventional

2. Study Status

Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
February 2005 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Hannover Medical School
Collaborators
Pall Corporation, B. Braun Melsungen AG

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether the use of in-line filtration shows any effect on the outcome of sepsis, systemic inflammatory response syndrome (SIRS), thrombosis, or organ failure in critically ill children admitted to the pediatric intensive care unit (PICU).
Detailed Description
Scientific background: Particulate contamination of infusion solutions and their systemic administration during infusion therapy has been linked to various clinical problems. Organ failure and Multi-Organ Failure (MOV): It is well established that the pathophysiology of MOV involves deteriorations of the microcirculation and integrity of endothelial cells. As a consequence of this an imbalance between pro- and anticoagulatory factors may develop and microthrombi may form. Mediators like tissue factor (TF) and platelet activating factor (PAF) have been linked to the formation of microthrombi. Particles have been discussed as a causative agent for this syndrome by various authors. Their effect on morbidity and mortality of patients has however not yet been established. Particles may have additional harmful effects: Direct thrombogenesis by the particle material Damaging endothelial cells in the capillary network Embolisation of the pulmonary vasculature Acting as a cristallisation focus for the development of granuloma Promoting the formation of Giant Cells Various authors have shown that the use of end line infusion filters significantly reduces the rate of thrombophlebitis. A recently published study by van Lingen et al. (2004) also showed that the use of end line infusion filters significantly reduced the rate of overall complications in neonates. Study Hypothesis: The use of end line positively charged 0.2 µm and uncharged 1.2 µm infusion filters will prevent particles, microorganisms and their endotoxins from the infusate to enter the patient's circulation in the study group and will reduce significantly the complication rate of these patients. The following clinical diagnoses are defined as "Complications". They are main contributors to morbidity and mortality in intensive care wards: catheter related thrombosis of the central veins sepsis with proven infectious organisms Septic syndrome without proven infectious organisms Failure of one of the following organs/systems Lung Kidney Liver Circulation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness
Keywords
pediatric intensive care, critically ill children, in-line filtration, prospective randomized study, complications, sepsis, SIRS, thrombosis, organ failure

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
821 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Filter: NOE96E, ELD96E, NLF1E, TNA1E
Primary Outcome Measure Information:
Title
Sepsis
Title
Thrombosis
Title
SIRS
Title
Organ failure
Title
Composite primary outcome including "sepsis, SIRS, thrombosis, organ failure"
Secondary Outcome Measure Information:
Title
Duration of Pediatric Intensive Care Unit stay
Title
Duration of overall hospital stay

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children admitted to pediatric intensive care unit (PICU) Exclusion Criteria: Suspected death within 48 hours Duration of PICU stay less than 6 hours Patients recruited for Simulect or Sintra Study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Sasse, Consultant
Organizational Affiliation
Medical School Hannover
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Thomas Jack, Doctor
Organizational Affiliation
Medical School Hannover
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hannover Medical School
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
29544449
Citation
Lamping F, Jack T, Rubsamen N, Sasse M, Beerbaum P, Mikolajczyk RT, Boehne M, Karch A. Development and validation of a diagnostic model for early differentiation of sepsis and non-infectious SIRS in critically ill children - a data-driven approach using machine-learning algorithms. BMC Pediatr. 2018 Mar 15;18(1):112. doi: 10.1186/s12887-018-1082-2.
Results Reference
derived
PubMed Identifier
23384207
Citation
Boehne M, Jack T, Koditz H, Seidemann K, Schmidt F, Abura M, Bertram H, Sasse M. In-line filtration minimizes organ dysfunction: new aspects from a prospective, randomized, controlled trial. BMC Pediatr. 2013 Feb 6;13:21. doi: 10.1186/1471-2431-13-21.
Results Reference
derived
PubMed Identifier
22527062
Citation
Jack T, Boehne M, Brent BE, Hoy L, Koditz H, Wessel A, Sasse M. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med. 2012 Jun;38(6):1008-16. doi: 10.1007/s00134-012-2539-7. Epub 2012 Apr 12.
Results Reference
derived

Learn more about this trial

Use of In-Line Filtration in Critically Ill Children

We'll reach out to this number within 24 hrs